Sugi Predict

Sugi Predict / Targets / MDM4

MDM4

Protein Mdm4 · O15151 · MDM4 on Sugi Atlas →

52,329 patent compounds predicted against MDM4, 37,504 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL222410 SCHEMBL222410 0.75 10/20
SCHEMBL222411 SCHEMBL222411 0.75 10/20
SCHEMBL222321 SCHEMBL222321 0.67 9/20
SCHEMBL222322 SCHEMBL222322 0.67 9/20
SCHEMBL221308 SCHEMBL221308 0.66 9/20
SCHEMBL221309 SCHEMBL221309 0.66 9/20
SCHEMBL222842 SCHEMBL222842 0.67 7/20
SCHEMBL222843 SCHEMBL222843 0.67 7/20
SCHEMBL222264 SCHEMBL222264 0.59 4/20
SCHEMBL222265 SCHEMBL222265 0.59 4/20
SCHEMBL222575 SCHEMBL222575 0.59 4/20
SCHEMBL222576 SCHEMBL222576 0.59 4/20
SCHEMBL119548 SCHEMBL119548 0.67 3/20
SCHEMBL120638 SCHEMBL120638 0.67 3/20
SCHEMBL119379 SCHEMBL119379 0.66 3/20
SCHEMBL118370 SCHEMBL118370 0.61 3/20
SCHEMBL118051 SCHEMBL118051 0.60 3/20
SCHEMBL119339 SCHEMBL119339 0.60 3/20
SCHEMBL178787 SCHEMBL178787 0.60 3/20
SCHEMBL223578 SCHEMBL223578 0.60 3/20

Clinical trials — most relevant to MDM4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia PHASE3COMPLETED
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease PHASE2RECRUITING
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer PHASE2RECRUITING
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation PHASE2UNKNOWN
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer PHASE1/PHASE2COMPLETED
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer. PHASE2UNKNOWN
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer PHASE2COMPLETED
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer PHASE2COMPLETED
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia PHASE1COMPLETED
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors PHASE1COMPLETED
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients nanRECRUITING
Molecular Markers in Cancers and Precancers (MOCA) nanWITHDRAWN
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers nanUNKNOWN
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma nanCOMPLETED
Tumor and Development (TED) nanCOMPLETED
Genetic Testing in Young Adults With Cancer Study nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MDM4 binder may also engage these)

ProteinNameSimilarity
Q2HJ21 — 1.000 Q2HJ21 →
Q5XIN1 — 1.000 Q5XIN1 →
O35618 — 1.000 O35618 →
P56951 — 0.991 P56951 →
Q7YRZ8 — 0.991 Q7YRZ8 →
MDM2 E3 ubiquitin-protein ligase Mdm2 0.989 landscape →
Q7ZYI3 — 0.989 Q7ZYI3 →
P56273 — 0.989 P56273 →
Q7ZUW7 — 0.988 Q7ZUW7 →
Q9NWN3 — 0.988 Q9NWN3 →
P23804 — 0.987 P23804 →
P56950 — 0.987 P56950 →
Q8NAT2 — 0.986 Q8NAT2 →
Q5VYS8 — 0.986 Q5VYS8 →
Q5W4S4 — 0.985 Q5W4S4 →
Q96S38 — 0.984 Q96S38 →
Q501R9 — 0.984 Q501R9 →
Q8BSV3 — 0.983 Q8BSV3 →
P97432 — 0.983 P97432 →
E2QTD3 — 0.983 E2QTD3 →
Q6GPJ8 — 0.982 Q6GPJ8 →
B2RX14 — 0.982 B2RX14 →
Q0VEE6 — 0.982 Q0VEE6 →
Q9DAU9 — 0.982 Q9DAU9 →
Q5RDQ6 — 0.981 Q5RDQ6 →
DDX20 Probable ATP-dependent RNA helicase DDX20 0.981 landscape →
Q99ME3 — 0.981 Q99ME3 →
Q80Y19 — 0.981 Q80Y19 →
Q8CCH7 — 0.981 Q8CCH7 →
Q8WW38 — 0.980 Q8WW38 →